Crispr Therapeutics shares tumble after significant earnings miss
David Aaron Lehman, General Counsel at Pulmonx Corp (NASDAQ:LUNG), recently executed a series of stock transactions, as disclosed in a recent SEC filing. On March 3, Lehman sold a total of 22,355 shares of Pulmonx common stock. These sales occurred at prices ranging from $7.14 to $7.97 per share, amounting to a total value of approximately $170,918. The timing of these sales coincides with the stock’s recent volatility, as InvestingPro data shows an 11% decline over the past week, despite a strong year-to-date return of over 20%.
The transactions were part of a pre-established trading plan designed to cover tax obligations related to the vesting of Restricted Stock Units (RSUs) granted in previous years. Following these transactions, Lehman holds 175,496 shares of Pulmonx stock. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 5.58 and holds more cash than debt on its balance sheet. Additionally, he received a grant of 108,000 RSUs, which will vest over the next four years. For deeper insights into Pulmonx’s financial health and valuation metrics, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Pulmonx Corp reported a strong fourth-quarter performance for 2024, with revenues reaching $23.8 million, marking a 23% increase from the previous year. The company’s earnings per share (EPS) of -$0.33 surpassed the forecasted -$0.4475, showcasing improved financial management and operational efficiency. Pulmonx’s U.S. revenue rose by 16% to $15.9 million, while international revenue surged by 42% to $7.9 million, reflecting successful international expansion efforts. Despite this growth, the company experienced a slight reduction in gross margins, which fell to 74% from 74.7% year-over-year.
Citi analysts responded to these results by raising the price target for Pulmonx shares to $8.00, up from $7.50, while maintaining a Neutral rating. This adjustment follows Pulmonx’s record revenue performance and indicates cautious optimism from analysts regarding the company’s growth potential. Pulmonx has provided guidance for 2025, projecting revenue between $96 million and $98 million, which represents a growth of 16%-18% excluding foreign exchange impacts. This guidance aligns closely with the consensus estimate of $97.7 million.
The company continues to focus on increasing physician adoption, exploring new indications, and expanding geographically. Pulmonx’s management is committed to establishing its Zephyr valve as the standard of care for COPD patients. As part of its growth strategy, Pulmonx is preparing for the launch of new products, such as the ARISEAL, expected to drive further growth in the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.